Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.» Read More
Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.
CNBC's Sheila Dharmarajan reports on what factors contribute to the biotech sector outperforming this year.
LONDON, Jan 29- In experiments that could open a new era in stem cell biology, scientists have found a simple way to reprogramme mature animal cells back into an embryonic-like state that allows them to generate many types of tissue.
LONDON, Jan 29- In experiments that could open a new era in stem cell biology, scientists have found a cheap and easy way to reprogramme mature cells from mice back into an embryonic-like state that allowed them to generate many types of tissue.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.
Dan Fitzpatrick, StockmarketMentor.com president & technical analyst, takes a look at the charts to get a technical read on Twitter. Also a look at why Fitzpatrick likes the biotech sector.
Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss its firm's success, and how rising yields impact its dividend.
Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss real estate demand in the biotech industry.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.
Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.
The Supreme Court upheld Monsanto's biotech seed patents on Monday, dealing a blow to organic farmers and critics of the company.
The outlook for biotech is "wonderful," explains Sam Isaly, Orbimed Advisors managing partner.
Shares of Intercept Pharmaceuticals are up more than 560 percent this week alone. Akiva Felt, Oppenheimer senior analyst, shares his optimistic view for the company.
Jan 6- Thermo Fisher Scientific Inc said it would sell three of its businesses to General Electric Co's healthcare unit for $1.06 billion, fulfilling a requirement for European antitrust approval to buy Life Technologies Corp..
Daryl Liew, Head Of Portfolio Management of REYL Singapore advises investors to look past short-term volatilities in the country's economy after Q4 GDP data missed expectations
The Food and Drug Administration, in a statement to healthcare professionals, said it is concerned that women will believe misleading claims about a nipple aspirate test and not get mammograms or other needed breast imaging tests or biopsies.
*Celgene to take 5 pct stake in OncoMed. *Celgene stock down 1.4 pct. Dec 3- Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs.
CNBC's Seema Mody reports the biotech index has hit an all-time high in the Nasdaq.